Abstract:OBJECTIVE:To measure the urokinase-type plasminogen activator (UPA) and its receptor (UPAR) in the plasma of patients with cerebral infarction and to study the effects of UPA and UPAR on cerebral infarction.METHODS:ELISA sandwich method was used to measure the plasma levels of UPA and UPAR in 89 patients with acute cerebral infarction, subdivided into mild, moderate and severe subgroups according to the modified Edinburgh-Scandinavia stroke scale (mESSS), and 30 patients with other disease and 30 healthy persons as controls.RESULTS:Within 2 days after the onset of cerebral infarction the UPA and UPAR levels were (1663.7 +/- 384.2) ng/L and (1 375.3 +/- 303.0) ng/L respectively, both significantly higher than those of the patients with other diseases [(1 033.0 +/- 122.7) ng/L and (978.3 +/- 120.0) ng/L respectively (P = 0.038 and P = 0.000)] and those of the normal control group [(1 005.0 +/- 128.9) ng/L and (904.7 +/- 158.6) ng/L respectively, both P = 0.000]. Two weeks after the onset of stroke, the plasma UPA level was (1 185.5 +/- 384.6) ng/L, not significantly different from those of the 2 control groups (both P > 0.05); while the plasma UPAR level in the cerebral infarction was (1 159.3 +/- 261.2) ng/L, significantly higher than those in the 2 control groups (P < 0.01). Within 2 days after the onset of infarction the plasma UPA and UPAR levels of the severe subgroup were (1 938.9 +/- 256.5) ng/L and (1 510.8 +/- 378.7) ng/L respectively, both significantly higher than those of the moderate subgroup [(1 593.7 +/- 204.8) ng/L and (1 296.6 +/- 151.2) ng/L respectively, both P < 0.01] and those of the mild subgroup [1 358.5 +/- 175.9] ng/L and (1 226.8 +/- 98.3) ng/L respectively, both P < 0.01], Two weeks after the onset of stroke,the plasma UPA and uPAR levels of the severe subgroup remained significantly higher than those of the mild subgroup [(1 152.6 +/- 170.3) ng/L vs (1 041.9 +/- 187.0) ng/L, (P < 0.05)] and [(1 186.4 +/- 158.3) ng/L vs (1 053.9 +/- 109.4) ng/L, (P < 0.01)]. In addition, the plasma UPA and UPAR levels of the patients who died from cerebral infarction at last were the highest among all the groups.CONCLUSION:The plasma levels pf UPA and UPAR increase in patients with cerebral infarction and may be related with the severity of disease. The UPA and UPAR genes may play an important role via proteolytic degradation of the extracellular matrix and basement membrane during the development of cerebral infarction.

The Expression of PPARγ Mrna in Peripheric Lymphocytes in Patients with Acute Cerebral Infarct

Study on the Changes of Serum Levels of Interleukin-1β(IL-1β) and C-Reactive Protein(CRP) in Patients with Acute Cerebral Infarction

Study on the Changes of Plasma Levels of Brain natriureticpeptide(BNP) and C-Reactive Protein(CRP) in Patients with Acute Cerebral Infarction

To study the relationship between PPARγ and cerebral ischemia-reperfusion injury

Analysis of correlation between oxidized low density lipoprotein and thrombus precursor protein with acute cerebral infarction

Expressions of neurotrophic factors,receptors mRNA and related proteins of peripheral blood lymphocyte in cerebral infarction patients

[Expression of Urokinase-Type Plasminogen Activator and Its Receptor in Plasma of Patients with Cerebral Infarction].

Change and Clinical Significance of Plasma CD62p, IL-6 in Patients with Cerebral Infarction

Down-Regulation of Platelet-Activating Factor Receptor Gene Expression During Focal Reversible Cerebral Ischemia in Rats

[Changes of Plasma CD62p Levels in Patients with Acute Cerebral Infarction].

The Research about the State of the Activated Blood Platelet of Cerebral Infarction Patients

Study on Platelet Activation and Platelet Parameters in Patients with Cerebral Infarction

Expression of PPARγ after Acute Spinal Cord Injury

Expression Pattern of Peroxisome Proliferator-Activated Receptors in Rat Hippocampus Following Cerebral Ischemia and Reperfusion Injury.

Intrleukin-1β Mrna Expression after Permanent Cerebral Ischemia in Rats

Clinical Significance of Changes of Plasma Hcy,ET and NPY Levels After Treatment in Patients with Cerebral Infarction

Changes of Serum IL-6 in Cerebral Infarcts

Clinical Significance of Measurement of Changes of Serum NSE and Plasma NPY Levels After Treatment in Patients with Acute Cerebral Infarction

Expression of costimulatory molecule OX40 in peripheral regulatory T cells and its clinical significance in patients with acute cerebral infarction

Expression and significance of adenylcyclase in patients with acute cerebral infarction and recovery stage

Variants on the Expression of CD54 and CD42b in Peripheral Blood of Patients with Acute Ischemic Stroke and Their Clinical Effects